Loading
Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma.
Caron Jacobson leads the immune effector cell therapy programme at Dana-Farber Cancer Institute. She was first author of the 2022 Lancet Oncology report of ZUMA-5, the phase 2 trial in which axicabtagene ciloleucel produced high and durable response rates in relapsed or refractory indolent non-Hodgkin lymphoma, the basis for its approval in follicular lymphoma. She also investigates CAR-T therapy in large B-cell lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tags lymphoma, car-t, cell-therapy.
Shares Follicular lymphoma and the tags lymphoma, car-t, cell-therapy.
Shares Dana-Farber Brigham Cancer Center, Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tags lymphoma, trialist.
Shares Marginal zone lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag lymphoma.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tags lymphoma, car-t.
Shares the tags lymphoma, trialist.